Clinical Trials
21 trialsNCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT06623656 2026-04-21
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT07020065 2026-04-15
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Swiss Cancer Institute
Phase 2 Recruiting
NCT05553834 2026-04-13
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
Duke University
Phase 2 Active not recruiting
NCT07001618 2026-04-03
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT06943664 2026-03-24
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
Phase 2 Not yet recruiting
NCT05401786 2026-03-12
RAD-IO
The Netherlands Cancer Institute
Phase 2 Active not recruiting
NCT06385262 2026-03-06
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Phase 2 Suspended
NCT07450183 2026-03-04
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1
Henry Ford Health System
Phase 2 Not yet recruiting
NCT06918132 2026-02-24
N-PLANC
Mayo Clinic
Phase 2 Recruiting
NCT06731270 2026-02-12
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
Phase 2 Recruiting
NCT06656598 2026-02-11
SPORADIC
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT07360743 2026-02-10
META-1
UNICANCER
Phase 2 Not yet recruiting
NCT07274384 2025-12-10
HYPERBOLIC
Università Vita-Salute San Raffaele
Phase 2 Not yet recruiting
NCT06917573 2025-11-19
PALACE
Fundación GECP
Phase 2 Recruiting
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT06088771 2025-05-08
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT06743581 2024-12-20
Dupi-Cemi
Centre hospitalier de l'Université de Montréal (CHUM)
Phase NA Not yet recruiting
NCT05501665 2024-10-17
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown